Showing results (411-420 of 422) with videos related to

Sort By:
Pageof 43
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Cancer Discovery|November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D Powderly, et al.
Cancer Cell|September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Nature Medicine|April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trialMartin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
The New England Journal of Medicine|September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J Anderson, Nadine G Rouphael, Alicia T Widge, et al.
Cancer Cell|November 1, 2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 43